JP2023543978A5 - - Google Patents
Info
- Publication number
- JP2023543978A5 JP2023543978A5 JP2023516587A JP2023516587A JP2023543978A5 JP 2023543978 A5 JP2023543978 A5 JP 2023543978A5 JP 2023516587 A JP2023516587 A JP 2023516587A JP 2023516587 A JP2023516587 A JP 2023516587A JP 2023543978 A5 JP2023543978 A5 JP 2023543978A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antagonist
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078485P | 2020-09-15 | 2020-09-15 | |
| US63/078,485 | 2020-09-15 | ||
| PCT/US2021/050143 WO2022060678A1 (en) | 2020-09-15 | 2021-09-14 | Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543978A JP2023543978A (ja) | 2023-10-19 |
| JP2023543978A5 true JP2023543978A5 (cg-RX-API-DMAC7.html) | 2024-09-25 |
Family
ID=80777346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516587A Pending JP2023543978A (ja) | 2020-09-15 | 2021-09-14 | がん患者を治療するためのpd-1拮抗薬及びlag3拮抗薬及びレンバチニブ又はそれの薬学的に許容される塩の併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240010729A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4213846A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023543978A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230069957A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116457016A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021344849A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3195058A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023003032A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022060678A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250064794A1 (en) * | 2021-08-10 | 2025-02-27 | Eisai R&D Management Co., Ltd. | A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib |
| WO2025040080A1 (en) * | 2023-08-21 | 2025-02-27 | Beigene Switzerland Gmbh | Treatment of esophageal cancer with anti-lag3, anti-pd-1 and chemotherapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240064733A (ko) * | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| US20190038713A1 (en) * | 2015-11-07 | 2019-02-07 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| BR112018012352A2 (pt) * | 2015-12-16 | 2018-12-11 | Merck Sharp & Dohme Corp. | anticorpos anti-lag3 e fragmentos de ligação ao antígeno |
| WO2019222075A1 (en) * | 2018-05-14 | 2019-11-21 | Merck Sharp And Dohme Corp. | Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist |
| JP2021534153A (ja) * | 2018-08-15 | 2021-12-09 | アイビバ バイオファーマ インコーポレイテッド | Vegfおよびtgfベータのマルチキナーゼ阻害剤およびその使用 |
| WO2020096917A1 (en) * | 2018-11-05 | 2020-05-14 | Merck Sharp & Dohme Corp. | Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer |
| JP7503056B6 (ja) * | 2018-11-07 | 2024-07-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗lag3抗体および抗pd-1抗体の共-製剤 |
| JP2023515675A (ja) * | 2020-03-05 | 2023-04-13 | メルク・シャープ・アンド・ドーム・エルエルシー | Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法 |
-
2021
- 2021-09-14 MX MX2023003032A patent/MX2023003032A/es unknown
- 2021-09-14 US US18/245,222 patent/US20240010729A1/en not_active Abandoned
- 2021-09-14 CA CA3195058A patent/CA3195058A1/en active Pending
- 2021-09-14 WO PCT/US2021/050143 patent/WO2022060678A1/en not_active Ceased
- 2021-09-14 KR KR1020237012134A patent/KR20230069957A/ko active Pending
- 2021-09-14 JP JP2023516587A patent/JP2023543978A/ja active Pending
- 2021-09-14 AU AU2021344849A patent/AU2021344849A1/en not_active Abandoned
- 2021-09-14 CN CN202180076962.3A patent/CN116457016A/zh active Pending
- 2021-09-14 EP EP21870037.5A patent/EP4213846A4/en not_active Withdrawn